Person: KARATOPRAK, CUMALİ
79 results
Search Results
Now showing 1 - 10 of 79
Publication bariatrik cerrahi sonrası ilk 6 aylık süreçte protein tozu kullanan ve kullanmayan kişilerde ağırlık ve vücut bileşiminin karşılaştırılması(2017-11-23T00:00:00Z) BATAR, NAZLI; KARATOPRAK, CUMALİ; KARATOPRAK, CUMALİPublication A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.(2013-05-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; PERU, C; ERKOÇ, R; YAVUZ, E; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİPublication PREMENOPOZAL KADINLARDA SIK GÖRÜLEN DEMİR EKSİKLİĞİ ANEMİSİNDE SORUN VİTAMİN K EKSİKLİĞİ OLABİLİR Mİ?(2018-10-10T00:00:00Z) KARATOPRAK, CUMALİ; KARAASLAN, TAHSİN; ŞEKERCİ, ABDÜSSELAM; OLGAÇ, ATİLLA; KARATOPRAK, CUMALİ; ŞEKERCİ, ABDÜSSELAMPublication Protective effect of dexpanthenol against nephrotoxic effect of amikacin: An experimental study(2017-05-01) Dogan, ELİF ECE; ERKOC, Reha; EKINCI, Iskender; HAMDARD, Jamshid; DONER, Baris; KARATOPRAK, CUMALİ; Coban, GANİME; Ozer, Omer Faruk; Kazancioglu, RÜMEYZA; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ; ÇOBAN, GANİME; ÖZER, ÖMER FARUK; KAZANCIOĞLU, RÜMEYZABackground: Amikacin has the largest spectrum among aminoglycosides, its nephrotoxic effect limits its utilization. Our purpose in this study is to review the protective effect of dexpanthenol against the nephrotoxic effect of amikacin, accompanied with histopathological and biochemical parameters.Publication Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with restless legs syndrome(2016-01-01T00:00:00Z) Halac, G.; Kilic, E.; Cikrikcioglu, M. A.; Celik, K.; Toprak-Erek, A.; Keskin, S.; Gultepe, I; Celik, R. S.; Ozaras, N.; Yildiz, A.; Aydin, S.; Akan, O.; Karatoprak, C.; Sekin, Y.; Asil, T.; KARATOPRAK, CUMALİ; ASİL, TALIPOBJECTIVE: The aim of this study was to assess the predisposition for atherosclerosis in patients with RLS through serum sLOX-1 (serum Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1) measurements.Publication Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin-s or Non-Hodgkin-s Lymphoma?(2015-09-01) ÇETIN, GÜVEN; ÖZKAN, T; AR, MC; EŞKAZAN, AE; AYER, M; CERIT, A; ÇIKRIKÇIOĞLU, MA; GÖZÜBENLI, K; Karatoprak, CUMALİ; UYSAL, BB; ERDEM, S; ERGÜL, N; TATAR, G; ÇERMIK, TF; ÇETİN, GÜVEN; KARATOPRAK, CUMALİ; ERDEM, ŞÜKRANObjective: Positron emission tomography and computed tomography (PET/CT) has become an important part of staging and treatment evaluation algorithms of lymphoma. We aimed to compare the results of PET/CT with bone marrow biopsy (BMB) with respect to bone marrow involvement (BMI) in patients with Hodgkin's lymphoma (HL) and aggressive non-Hodgkin's lymphoma (aNHL). Materials and Methods: The medical files of a total of 297 patients diagnosed with HL or aNHL and followed at the hematology clinics of 3 major hospitals in Istanbul between 2008 and 2012 were screened retrospectively and 161 patients with classical HL and aNHL were included in the study. The patients were referred for PET/CT and BMB at the initial staging. BMB was performed as the reference standard for the evaluation of BMI. Results: There were 61 (38%) HL and 100 (62%) aNHL patients. Concordant results were revealed between PET/CT and BMB in 126 patients (78%) (52 HL, 74 aNHL), 20 with positive PET/CT and BMB results and 106 with negative PET/CT and BMB results. There were discordant results in 35 patients (9 HL, 26 aNHL), 16 of them with positive BMB and negative PET/CT results and 19 of them with negative BMB and positive PET/CT results. Conclusion: We observed that PET/CT is effective to detect BMI, despite it alone not being sufficient to evaluate BMI in HL and aNHL. Bone marrow trephine biopsy and PET/CT should be considered as mutually complementary methods for detection of BMI in patients with lymphoma. In suspected focal involvement, combining biopsy and PET/CT might improve staging results.Publication Serum endocan levels in women with restless legs syndrome.(2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREMBackground: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosisPublication Evaluation of the relationship between vitamin D level and adropin, IL-1β, IL-6, and oxidative status in women(2022-01-01T00:00:00Z) ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; Güler, Eray Metin; Gülen, Bedia; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFABackground: Vitamin D, adropin, proinflammatory cytokines, and oxidative stress closely related with metabolic homeostasis and endothelial dysfunction. The aim of the present study is to investigate how vitamin D levels affect serum adropin, IL-1ß, IL-6, and oxidative stress. Methods: A total of 77 female subjects were divided into 3 groups according to vitamin D levels. Biochemical parameters, adropin, IL-1ß, IL-6, oxidative stress markers were studied in these groups, and the results were compared statistically. Results: Serum adropin, IL-1ß, IL-6, total oxidant status (TOS) and total antioxidant status (TAS) and oxidative stress index (OSI) levels differed significantly between the vitamin D groups (p < 0.05). A significant positive correlation was detected between vitamin D, and adropin and TAS (r = 0.807; p < 0.001, r = 0.814; p < 0.001, respectively). A significant negative correlation was detected between vitamin D, and IL-1ß, IL-6, TOS, OSI (r = -0.725; p < 0.001, r = -0.720; p < 0.001, r = -0.238; p = 0.037, r = -0.705; p < 0.001, respectively). Discussion: Vitamin D could show its effects through vitamin D receptors on tissues or on the ENHO gene in adropin secreting tissues via direct or indirect mechanisms. Proinflammatory cytokines, oxidative stress, and adropin targeted studies could contribute to the prevention and treatment of diseases associated with vitamin D deficiency in future.Publication Dirençli Hipertansiyonlu Hastalarda H. Pylori Sıklığı Ve H. Pylori Eradikasyonun Yüksek Kan Basıncı Üzerine Etkisi.(2017-10-14T00:00:00Z) Karatoprak, Cumali; Hamdard, Jamshid; Bacaksız, Ahmet; KARATOPRAK, CUMALİ; BACAKSIZ, AHMETAims: Helicbacter pylorinin (H. pylori) ekstraintestinal olarak birçok patolojiye neden olduğu bilinmektedir. H. pylori eradikasyonunun primer hipertansiyon üzerinde pozitif etkileri olduğunu gösteren çalışmalar mevcuttur. Bu çalışmada biri diüretik olmak üzere 3 antihipertansif ilaç kullanımına rağmen sistolik kan basıncının >140 mm-Hg ve diyastolik kan basıncının >90 mm-Hg olan dirençli hipertansif hastalarda H. pylori sıklığı ve eradikasyonun kan basıncı kontrolü üzerine etkisi araştırılmıştır.Materials and Methods: Bu çalışma prospektif gözlemsel bir çalışmadır. Hastalardan gaitada H.pylori antijeni bakılan ve dirençli hipertansiyonu olan hastalar toplandı. Bütün hastaların ambulatuvar kan basınç monitörizasyonu ile 24 saatlik kan basınçları ölçüldü ve ortalama kan basıncı sistolik 140 mmhg ve/veya diastolik 90 mm-Hg’nın üzerinde olan hastalar çalışmaya alındı. Çalışmaya uygun bulunan hastalar H.pylori pozitif olanlar bir grup negatif olanlar diğer grup olmak üzere ikiye ayrıldı. H. pylori antijeni negatif olan hastalarda tedaviye uyum, tuzsuz beslenme ve kilo vermenin önemi anlatılarak 6 hafta sonra kontrole çağrıldı ve 24 saatlik kan basıncı monitorizasyonu tekrar yapıldı. H. pylori antijeni pozitif olan hastalara 14 günlük standart (lansoprozol, amoksisilin ve klaritromisin) H. pylori eradikasyon tedavisi verildi. Eradikasyon tedavisi bittikten 4 hafta sonraki kontrollerinde dışkıda H. pylori antijeni negatif olanlarda eradikasyon başarılı kabul edildi. Dirençli esansiyel hipertansiyonlu hastalarda 6 haftalık aralarla elde edilen sistolik ve diyastolik kan basınçları karşılaştırıldı.Results: Çalışmaya 12 H. pylori (+) 37 H. pylori (-) olmak üzere toplam 49 hasta katılmıştır.Bu çalışmada H. pylori sıklığı %24.5 bulunmuştur. H.pylori (+) hastalar tedavi edildiğinde hem sistolik (26.7 mm-Hg) hemde diastolik (9 mm-Hg) kan basıncında anlamlı düşüşler gözlenmiştir (P=0.002, P=0.011 respectively). Diğer taraftan H.pylori (-) olanlarda tedavi uyumunun arttırılmasına yönelik önerilere rağmen hem sistolik (-0.5 mm-Hg) hem de diastolik (0.3 mm-Hg) kan basıncında anlamlı bir değişiklik olmamıştır (P=0.52, P=0.73, sırasıyla). Conclusion: Bu sonuçlar direçli hipertansiyonu olan hastalarda H. pylori aranması gerektiğini düşündürmektedir. Ve eğer H. pylori pozitif saptanırsa eradikasyon tedavisinin arterial kan basıncı kontrolunu sağlamada yardımcı olabileceğini düşündürmektedir.Publication Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease(2013-09-01) Karatoprak, CUMALİ; CIKRIKCIOGLU, M. A.; Cakirca, MUSTAFA; Kiskac, MUHARREM; Zorlu, MEHMET; Cetin, GÜVEN; YILDIZ, KEMALETTİN; ERKOC, R.; ALAY, M.; Erkal, S.; Erkal, S. N.; DOGAN, S.; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇETİN, GÜVEN; YILDIZ, KEMALETTİN; KAZANCIOĞLU, RÜMEYZAAim: To search whether calcium channel blockers (CCBs) are associated with lower hemoglobin levels in chronic kidney disease (CKD) patients who are not on renal replacement therapy (RRT), vitamin D and anti-anemic treatment. Patients and methods: CKD patients were classified into two groups. Patients on CCBs treatment (103 patients) and patients not using CCBs (104 patients) were compared cross-sectionally regarding clinical findings, complete blood count (CBC), biochemistry and regular medication use. Patients with polycystic kidney disease, comorbidities that could influence CBC other than iron deficiency of obscure origin, patients receiving RRT, erythropoietin (EPO), vitamin D, phosphate binders and drugs that could influence CBC were excluded. Under dependent variable of CCB use, all significantly different independent variables were subjected to multivariate binary logistic regression analysis (MBLRA). Results: Lower hemoglobin, lower bilirubinemia, higher serum EPO, higher systolic blood pressure were observed in CCB users. Two groups were similar concerning age, gender, BMI, CKD etiology, CKD stage, pretibial edema prevalence, cardiothoracic index, diastolic blood pressure, corrected reticulocyte count, BUN, creatinine, eGFR, proBNP, parathormone, alkaline phosphatase, phosphorous, corrected calcemia, sCRP, relative EPO deficiency and prevalence of relative EPO deficient patients. Groups were comparable regarding comorbidities, types and usage frequencies of all antihypertensive medications other than CCBs. Higher systolic blood pressure and lower hemoglobin were significantly associated with CCB use after MBLRA. Conclusions: Hemoglobin was significantly lower in CCB users compared to non-users, among CKD patients who did not receive RRT, EPO, phosphate binders, vitamin D, iron, vitamin B12 and folic acid.